Oncology Nurse Advisor2d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The American Journal of Managed Care7d
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
Morningstar17d
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
including the potential of CG001419 to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain; the study design for the Phase 1 healthy volunteer ...
pharmaphorum8d
Levicept says non-opioid drug cuts arthritis pain in phase 2
has shown it can reduce pain associated with osteoarthritis in a phase 2 trial. Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled ...
Nasdaq10d
OKYO Pharma Starts Phase 2a Trial Of OK-101 For Neuropathic Corneal Pain, Enrollment By Q2 2025
on Wednesday announced the initiation of its Phase 2a clinical trial for OK-101, a novel non-opioid therapeutic candidate aimed at treating neuropathic corneal pain or NCP. The company anticipates ...